All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Infusions of HLA-mismatched Granulocyte Colony-Stimulating Factor (G-CSF)-mobilized Peripheral Donor Blood Stem Cells (GPBSCs) in combination with chemotherapy have been reported to result in a high Complete Remission (CR) rate, a longer survival time, and a shorter duration of pancytopenia than conventional chemotherapy alone in elderly Acute Myeloid Leukemia (AML) patients.1 However, the optimal cytoreductive therapy in combination with GPBSCs is not well understood yet.
In an article published in Leukemia & Lymphoma, Wei-Yang Li et al. from the Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China, discussed results from their retrospective study which assessed the safety and efficacy of decitabine (DAC) in combination with intermediate-dose cytarabine (ID-Arac) followed by GPBSCs as consolidation treatment in older AML patients in CR1.
In total, 42 consecutive AML patients (median age = 63 years, range, 60–74 years) who were enrolled in this study. Twenty-three patients received DAC and ID-AraC followed by GPBSCs (D-GPBSCs group) while the remaining 19 patients received ID-AraC alone (chemo group).
In summary, DAC plus ID-AraC followed by subsequent GPBSCs was well tolerated and improved the survival of elderly AML patients. Key limitations of this study include its retrospective nature and small size.
The authors concluded by suggesting that a prospective study optimizing the schedule, dosing and timing of DAC plus ID-AraC followed by GPBSCS is warranted as this regimen might be a promising possibility for elderly AML patients.
This retrospective study tested the feasibility of decitabine (DAC) plus intermediate-dose cytarabine (ID-AraC) followed by HLA-mismatched granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral donor blood stem cells (GPBSCs) infusion as consolidation treatment for older patients with acute myeloid leukemia (AML) in first complete remission (CR). A total of 23 patients received this regimen for 3 cycles (D-GPBSCs group), and the outcome was compared with that of 19 patients treated with repeated cycles of ID-AraC chemotherapy (chemo group). The two regimens were well tolerated. The median recovery times for neutrophils and platelets were shorter in D-GPBSCs group than in chemo group (p<.05). No graft-versus-host disease (GVHD) was observed in D-GPBSCs group. The 2-year leukemia-free survival (LFS) and overall survival (OS) were better in D-GPBSCs group (51.6 and 55.4%) than in chemo group (27.1 and 34.2%) (p = .047 and p = .056). These data suggest that DAC and ID-AraC followed by GPBSCs as a consolidation regimen may be a safe and promising option for older patients with AML.
Subscribe to get the best content related to AML delivered to your inbox